Dassault Systemes announced it collaborated with CDR-Life to accelerate CDR-Life's development of next-generation highly tumor-selective immunotherapies using CDR-Life's proprietary M-gage platform. Scientists from Dassault Systemes' Contract Research team worked closely with scientists from CDR-Life to perform virtual "what if" experiments on antibody-based biologics called T-cell engagers, using Dassault Systemes' BIOVIA software and CDR-Life's experimental data. Dassault Systemes' Contract research team leveraged its expertise in science and technology to model different molecules virtually, and identify ones that will have desirable properties such as stability, without impacting other molecular function.

Following a holistic and systemic analysis of the results, the team provided the variants that were anticipated to have a high probability of success when tested in the lab by CDR-Life. Next generation immunotherapies are a key step in the successful treatment of cancer, as they empower the immune system to eradicate malignant cells with unparalleled specificity. Improving the stability of antibody-based T-cell engagers can result in high tumor cell killing potency, longer duration of effect, and lower risk of immune-related adverse effects.